|
ZNF551 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.17920007092209E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.07440001340109E-09 |
| Normal-vs-Stage2 |
9.33360000399119E-09 |
| Normal-vs-Stage3 |
9.44722078344284E-12 |
| Normal-vs-Stage4 |
4.74030037445061E-10 |
| Stage1-vs-Stage2 |
7.363000E-01 |
| Stage1-vs-Stage3 |
1.865910E-02 |
| Stage1-vs-Stage4 |
5.665800E-02 |
| Stage2-vs-Stage3 |
2.006800E-01 |
| Stage2-vs-Stage4 |
2.371800E-01 |
| Stage3-vs-Stage4 |
9.031000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.42969969196827E-10 |
| Normal-vs-AfricanAmerican |
7.64880000000412E-05 |
| Normal-vs-Asian |
4.53139999967433E-07 |
| Caucasian-vs-AfricanAmerican |
6.002400E-01 |
| Caucasian-vs-Asian |
1.581220E-01 |
| AfricanAmerican-vs-Asian |
6.586000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.29529720283017E-11 |
| Normal-vs-Female |
7.48829886987323E-11 |
| Male-vs-Female |
4.194000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.77859998635222E-10 |
| Normal-vs-Age(41-60Yrs) |
4.23750035061232E-10 |
| Normal-vs-Age(61-80Yrs) |
2.36644037698852E-12 |
| Normal-vs-Age(81-100Yrs) |
1.098690E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.164000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.658400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.482000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.768580E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.121400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.891800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.3867000003831E-07 |
| Classical-VS-Follicular |
1.699350E-01 |
| Classical-VS-Other |
7.609800E-01 |
| Classical-VS-Normal |
6.95780000281587E-09 |
| Tall-VS-Follicular |
4.788900E-04 |
| Tall-VS-Other |
1.769780E-01 |
| Tall-VS-Normal |
1.63768998362457E-12 |
| Follicular-VS-Other |
8.862200E-01 |
| Follicular-VS-Normal |
1.32249999840184E-09 |
| Other-VS-Normal |
8.799500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.32169983028064E-10 |
| Normal-vs-N1 |
1.84710002848476E-09 |
| N0-vs-N1 |
3.287600E-01 |
|
|
